A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

Key Inclusion Criteria:

• Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40.
• Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3.
• Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study.

Key Exclusion Criteria:

• Any condition that would compromise the safety or feasibility of lumbar puncture or magnetic resonance imaging (MRI).
• Presence of other significant neurological or systemic illnesses.
• Current, chronic or active human immunodeficiency virus, hepatitis B/C.
• Recent use of investigational agents or HTT-lowering therapies.
• Uncontrolled psychiatric illness or substance use disorders.
• Pregnancy or lactation.

Note: Other inclusion/exclusion criteria apply.